Research
Premium Reports
Decision-grade industry intelligence for leadership teams and investors. Built from operator interviews and regulatory analysis that does not appear in analyst reports.
The Isotope Production Map: Q2 2026
Facility-level production data, supply sufficiency verdicts, and strategic intelligence across 38 isotopes
Maps the global radiopharmaceutical isotope supply chain with facility-level precision across 38 isotopes and four production categories. Every supply sufficiency verdict, facility tracker, and fragility assessment reflects the state of play as of Q2 2026. Identifies five correlated fragility clusters where single infrastructure failures cascade across apparently unrelated clinical programmes.
View full product pageSingle-user PDF
Buy Individual LicenseKey Topics Covered
Ac-225 supply deficit: why capital cannot close the 2026-2028 gap
Mo-99/Tc-99m: the diagnostic backbone running on 1960s-era reactors
De-Russification of enriched stable isotopes (Yb-176, Gd-160)
Five correlated fragility clusters across the isotope landscape
Lu-177, At-211, Pb-212: supply sufficiency verdicts by isotope
Four-year outlook 2027-2030: commissioning, alpha pressure, scale-up
Physics dictates architecture: half-life determines supply chain model
Precursor and feedstock supply: Ra-226, Th-229, Yb-176, Gd-160 tracking
The State of Radiopharmaceuticals 2026
The definitive operating-reality assessment of the global radiopharmaceutical sector
A systems-level deconstruction of the radiopharmaceutical industry covering isotope supply-chain fragility, the alpha emitter transition, manufacturing scale-up constraints, NRC/FDA regulatory divergence, radiation-qualified talent scarcity, and capital reallocation. Built from executive search mandate intelligence across 50+ radiopharma organisations.
Single-user PDF
Buy Individual LicenseKey Topics Covered
Isotope supply: Ac-225, Pb-212, At-211 production realities and bottlenecks
Manufacturing: alpha-ready facility requirements vs beta-legacy infrastructure
Regulatory: dual NRC/FDA oversight, international divergence, inspection readiness
Talent: the Authorised User bottleneck and radiation-qualified workforce scarcity
Capital: where institutional money is moving and why valuations face stress
Competitive landscape: vertical integrators vs platforms vs radiopharma CDMOs
Weaponised Capacity: The CDMO Report 2026
Why capacity no longer wins and where value is migrating in contract manufacturing
The definitive guide to CDMO strategy, selection, and valuation in the post-BIOSECURE era. Dissects the structural reset across global contract manufacturing and maps which operators will compound value vs. quietly fail this cycle.
Single-user PDF
Buy Individual LicenseKey Topics Covered
The three-force collision: sovereignty, complexity, and talent
Ghost capacity: why announced capacity does not equal schedulable output
BIOSECURE Act and the fracturing of global pharmaceutical supply chains
PE-backed CDMOs: exit pressure, platform fatigue, and consolidation dynamics
Complexity premium: ADC, viral vector, and radiation-grade manufacturing
CDMO talent scarcity: where the qualified people are and are not